{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoLmwuuoLDA","founded_year":2014,"lastupdate":"2023-02-22T00:00:00.000Z","update_date":"2023-02-22T00:00:00.000Z","lastModified":"Jan 27, 2025","confidence_score":68,"active":1,"confidence_score_reason":"product stage, sector, business model, video or image, markets, not claimed","urlname":"adicet-bio","minimal_profile":null,"status":"Public","fullstatus":"Public on NASDAQ on Sep, 2020;","acquired":0,"description_edited":1,"tag_line_edited":1,"phone":"","registrar":null,"biverification":"Jenny Sotnik-Talisman","recentupdates":[{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-22 17:08:41.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-22 17:07:54.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 16:22:26.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-22 17:10:25.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-22 17:10:50.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-07 16:33:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"matane@sncentral.org","source":"Automatic","datetime":"2024-12-11 14:59:19.000000","last_name":"Eblagon","first_name":"Matan"},{"email":"matane@sncentral.org","source":"Automatic","datetime":"2025-01-27 06:03:34.000000","last_name":"Eblagon","first_name":"Matan"},{"email":"matane@sncentral.org","source":"Automatic","datetime":"2024-12-11 14:59:19.000000","last_name":"Eblagon","first_name":"Matan"},{"email":"maor.perlov@sncentral.org","source":"Automatic","datetime":"2023-01-07 16:33:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-07 16:33:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-07 16:33:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-22 17:10:50.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-22 17:07:54.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 08:02:50.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-01-25 08:02:50.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:58:58.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-07 16:33:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-22 17:07:54.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yotamm1988@gmail.com","source":"Manual","datetime":"2022-02-22 13:30:03.000000","last_name":"Maman","first_name":"Yotam"},{"email":"yotamm1988@gmail.com","source":"Manual","datetime":"2022-02-22 13:31:32.000000","last_name":"Maman","first_name":"Yotam"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2021-12-07 18:21:23.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2021-12-07 18:21:17.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yotamm1988@gmail.com","source":"Manual","datetime":"2022-02-22 13:31:15.000000","last_name":"Maman","first_name":"Yotam"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:50:32.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:30:48.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:27:36.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:27:42.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2018-06-28 04:20:11.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:23:09.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:23:09.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:23:09.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:23:09.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:22:28.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:22:28.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:22:28.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:47:27.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-24 12:20:37.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-24 12:19:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-24 12:19:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-24 12:19:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-24 12:19:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-24 12:19:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-24 12:19:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-24 12:19:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:19:55.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2018-06-27 08:07:51.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:24:58.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:24:58.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2018-06-28 04:20:33.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2018-06-28 04:20:33.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2018-06-28 04:20:33.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:47:30.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:47:28.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:47:29.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:25:36.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:24:31.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:25:52.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:45:54.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:19:10.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:19:10.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-06-26 08:47:26.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"liorkarol@gmail.com","source":"Manual","datetime":"2018-06-26 11:23:15.000000","last_name":"Karol","first_name":"Lior"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-03-30 13:56:25.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-03-30 13:43:36.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-03-30 13:54:16.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-03-30 13:45:42.000000","last_name":"Perlov","first_name":"Maor"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-31 11:56:40.000000","last_name":"McCandless","first_name":"Katie"},{"email":"yotamm1988@gmail.com","source":"Manual","datetime":"2021-03-30 13:43:35.000000","last_name":"Maman","first_name":"Yotam"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-03-30 14:01:14.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yotamm1988@gmail.com","source":"Manual","datetime":"2020-05-31 08:44:30.000000","last_name":"Maman","first_name":"Yotam"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-03-30 13:44:16.000000","last_name":"Perlov","first_name":"Maor"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-19 16:46:12.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-19 16:46:12.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-19 16:46:12.000000","last_name":"McCandless","first_name":"Katie"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2019-10-03 06:15:14.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-03-30 13:56:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2021-03-30 13:56:22.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-07 16:33:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-22 17:10:50.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 15:15:43.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-02-13 06:54:21.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:08:02.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-07 16:33:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-22 06:29:29.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-22 17:07:54.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-07 16:33:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-01-07 16:33:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-22 17:08:51.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-02-22 17:07:54.000000","last_name":"Perlov","first_name":"Maor"}],"sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2020-05-31T00:00:00.000Z","crunchbaseid":"adicet-bio","lastupdator":"Maor Perlov","lastupdator_email":"maor.perlov@sncentral.org","creator":"Yamila Silbert","creator_email":"yamila.urwicz@gmail.com","createdate":"2018-06-24T00:00:00.000Z","lastupdatedate":"2023-02-22","hide_reason":null,"hide_reason_data":null,"logokey":"$KQ6kToraT4NEfeKAnZ6Yp1ascOVlqB9MKFAM8alQARaOWykOaWHU6I","name":"Adicet Bio","israeliacquisitions":1,"forbesranking":null,"investmentarm":null,"investmentarmname":null,"hubname":null,"acquired_amount":null,"acquired_by":null,"acquired_country":null,"acquired_month":null,"acquired_year":null,"type":"Multinational","formernames":["resTORbio"],"alternativenames":[""],"country":"United States","inisraelsince":"2/2016","inisraelsincemonth":"2","isisraeli":0,"marketcapital":114941084,"marketcapitaldate":"2025-11-01T14:07:50.000Z","oneliner":"Pharmaceuticals","website":"http://www.adicetbio.com","employees":"11-50","employees_exact":12,"employees_overall":"1-500","employees_overall_exact":137,"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/10701436","instagram":""},"social":["https://www.linkedin.com/company/10701436"],"flattenedsociallinks":"https://www.linkedin.com/company/10701436","apps":{"appstore":"","googleplay":""},"investmentstage":[],"about":"Adicet Bio Inc is a preclinical-stage biotechnology company engaged in the design and development of immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies. The company's development is based on gamma delta T cells engineered with chimeric antigen receptors or T-cell receptors.\r\n\r\nIn 2016, Adicet Bio Inc acquired Israeli company Applied Immune Technologies (AIT), which develops immunotherapies. AIT, today called Adicet Bio Israel, continues its operations in Israel as Adicet's wholly owned subsidiary.","founded":"1/2014","team":[{"name":"Chen  Schor","email":"CSchor@adicetbio.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4IedsPgIDA","bounced":false,"claimed":0,"founder":0,"urlname":"chen-schor","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgu5Cd8wgM","position":"President & CEO","last_name":"Schor","claimtoken":"9qZx8s9qkjk5kRLsdUYoNTFCA8msJoybPPqrMnxxuL07b8VgifUQJT","first_name":"Chen ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/chen-schor-01b7a588/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-02-22 17:10:49.000000","initials":"CS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Reut Erel-Segal","email":"","phone":"","gender":"Female","userid":"ozMar3sX5c6iQdc9qHnJTrFsWW9Q8VRMdvxddzipB7VcyqKo3CU0OT","bounced":false,"claimed":null,"founder":0,"urlname":"reut-erel-segal","visible":1,"memberid":"EIWwxfsja2jhLO1gocfWpSZG7jaW5l5O2dt9jvIrI2MtqoVIwMxmg0","position":"Scientific research team leader","last_name":"Erel-Segal","claimtoken":null,"first_name":"Reut","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/reut-erel-segal-96760176/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"RE","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"portfolio":[{"name":"Applied Immune Technologies","hidden":false,"raised":"$4.4M","founded":"2006","fullurl":"/company_page/applied-immune-technologies","logokey":"$Z69ouFOYUtThyIhsUicBpVwaMdSbeRv3j5bf9iW5oHSGkcGhchTKlG","urlname":"applied-immune-technologies","employees":"1-10","company_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgL6qvK8KDA","description":"TCRL Antibodies for Therapeutic Applications","fundingstage":"Acquired","businessmodel":"B2B","raisedNumber":4400000,"logourl":"https://storage.googleapis.com/clean-finder-353810/$Z69ouFOYUtThyIhsUicBpVwaMdSbeRv3j5bf9iW5oHSGkcGhchTKlG","style":"","hiddenCompanyTooltip":""}],"exits":[],"mediagallery":[],"affiliatedOrganizations":null,"address":{"israeli":[{"id":"c874df01-febd-4a0b-ac66-c261e2f96de5","city":"Haifa","type":["R&D"],"address":"Sderot Chicago 1, Haifa, Israel","placeid":null,"notactive":0,"openeddate":"2016-02-01","registrarid":"513800649","firstrdcenter":0,"registrarname":"Adicet Bio Israel Ltd"}],"officesabroad":[{"id":"tmx3XvUGQ96IpdtwUmoVkdsRE29bcMtAjntIX11LDjkkBhDXH3ym8w","city":null,"address":"Israel","country":"Israel","placeid":"ChIJi8mnMiRJABURuiw1EyBCa2o"}]},"headquarter_address":"Menlo Park, CA, USA","news":[{"id":"ce6a7f1c-77ac-4040-b382-8967baf6f74d","date":"Dec 6, 2021","link":"https://www.globenewswire.com/news-release/2021/12/06/2346413/0/en/Adicet-Bio-Announces-Positive-Interim-Clinical-Data-From-First-Ever-Allogeneic-Off-The-Shelf-Gamma-Delta-CAR-T-Investigational-Cell-Therapy.html","source":"www.globenewswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"rBhONW4vV5AQ61QphUx64loD147pHc2Fb4jYdLr6chAyl1XHrdPYjW","news_summary":"Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"2588a569-01ea-401d-b58f-3971470fc8cf","date":"Sep 15, 2020","link":"https://www.globenewswire.com/news-release/2020/09/15/2093777/0/en/Adicet-Announces-Completion-of-Merger-with-resTORbio.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":["merger","public trading","management changes"],"company":"Adicet Bio, Inc.","layoffs":null,"summary":"Adicet Bio, Inc. has completed its merger with resTORbio, Inc. and will begin trading on the Nasdaq Global Market under the ticker symbol ACET. The company focuses on developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet plans to advance its pipeline of gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies, to enhance tumor targeting and improve immune response. The merger transaction resulted in a 7:1 reverse split of resTORbios common stock. Adicet anticipates filing an IND for ADI-001 CD20 gamma delta CAR-T and initiating a Phase 1 clinical study for non-Hodgkins lymphoma. The company also plans to file an IND for ADI-002 GPC3 gamma-delta CAR-T and initiate a Phase 1 clinical study for hepatocellular carcinoma and other solid tumors. The merger was advised by JMP Securities LLC, and the combined company will be led by Chen Schor as President and CEO.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["merger","gamma delta T cell therapy","pipeline","clinical studies","leadership team"],"date_of_event":"September 16, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition","Public Trading","Management Changes"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition  #Public Trading  #Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"aPOxDSUPow12V4dpTkpnQWPKtm3JhA08Qw5D7Kyh71L1fkb4MgLvyq","news_summary":"Adicet Announces Completion of Merger with resTORbio","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a5445ae1-4a9c-4faf-82ed-588b6f3b71b8","date":"Apr 29, 2020","link":"https://www.globenewswire.com/news-release/2020/04/29/2024073/0/en/resTORbio-and-Adicet-Bio-Announce-Merger-Agreement-to-Advance-Allogeneic-Gamma-Delta-CAR-T-Cell-Therapy-Technology.html","source":"www.globenewswire.com","visible":1,"analysis":{"tags":"Merger, Investment","company":"Adicet Bio, Inc. and resTORbio, Inc.","layoffs":"Not mentioned","summary":"Biopharmaceutical companies resTORbio, Inc. and Adicet Bio, Inc. have announced a definitive merger agreement to create a combined publicly-traded biotechnology company focused on the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications. Under the terms of the agreement, Adicet would merge with a wholly-owned subsidiary of resTORbio in an all-stock transaction, and the equityholders of Adicet will become the majority owners (75%) of resTORbio’s outstanding common stock upon the close of the merger. The transaction is expected to close in the second half of 2020.","partners":"Regeneron Pharmaceuticals, Inc.","customers":"Not mentioned","investors":"OrbiMed Advisors, aMoon2 Fund, Novartis Venture Fund, Regeneron Pharmaceuticals, Inc., Johnson & Johnson Innovation – JJDC, Inc. (JJDC), OCI Enterprises, Inc, KB Investment Co., Ltd., Consensus Business Group, SBI JI Innovation Fund, Samsung Venture Investment Corporation, Handok, Inc., DSC Investment, Inc. and Pontifax","confidence":9,"key_topics":"Merger, Investment, Cell Therapy, Stock Transaction, Leadership","date_of_event":"April 29, 2020","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$80 million Series B financing","structured_issues":"Acquired-by, Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Acquired-by, Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"LEaB4150eRzwQNhD6W5zHMgfisO1iCPwysa0vbTlixAi9m9oGTRQxY","news_summary":"resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"B64yAYXffOAFb2NRRXAd0okiZBvQT8HjzdS9UrjFGfVr77BEYCnQBM","date":"Oct 3, 2019","link":"https://en.globes.co.il/en/article-amoon-invests-in-80m-adicet-bio-financing-round-1001302611","source":"en.globes.co.il","visible":1,"analysis":{"tags":"biopharmaceutical, cell therapies, cancer, financing","company":"Adicet Bio Inc.","layoffs":null,"summary":"Adicet Bio Inc., a US biopharmaceutical company, has raised $80 million in a Series B financing round. The funding was led by new investors including Marius Nacht and Dr. Yair Schindels aMoon2 Fund, with participation from existing investors. Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells. The financing will allow the company to continue developing their proprietary technology and advance their programs in Non-Hodgkins Lymphoma and solid tumors.","partners":null,"customers":null,"investors":["Marius Nacht","Dr. Yair Schindel","Regeneron Pharmaceuticals","Johnson & Johnson Innovation","OCI Enterprises","KB Investment","Consensus Business Group","SBI JI Innovation Fund","Samsung Venture Investment Corp","Handok","DSC Investment","OrbiMed","Novartis Venture Fund","Pontifax"],"confidence":9,"key_topics":["Series B financing","cell therapies for cancer","gamma delta T cells","new investors","existing investors"],"date_of_event":"October 3, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$80 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"HRBFgiMzdHzNBtMk7tPZdAmayU18Gmad6fCbgoWcKLGArulyFPHuyZ","news_summary":"aMoon invests in $80m Adicet Bio financing round","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"40a96d32-9119-4f8c-b4c2-cdb337defe23","date":"Oct 2, 2019","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3771364,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"funding","company":"Adicet Bio Inc.","layoffs":null,"summary":"Adicet Bio Inc., a Menlo Park-based allogenic immunotherapy company, has raised an $80 million series B funding round. The funding round was participated by Johnson & Johnson Innovation, aMoon2 Fund, Samsung Venture Investment Corp., and existing investors Orbimed Israel Partners Ltd., Novartis Venture Fund, and Pontifax Ltd. Adicet develops universal immune cell therapies based on gamma delta T cells to treat different forms of cancer. The company plans to use the funding to develop its proprietary technology for the treatment of Non-Hodgkin’s Lymphoma. Adicet has raised a total of $131 million to date and employs a team of 61 people in the U.S. and Israel.","partners":null,"customers":null,"investors":["Johnson & Johnson Innovation","aMoon2 Fund","Samsung Venture Investment Corp.","Orbimed Israel Partners Ltd.","Novartis Venture Fund","Pontifax Ltd."],"confidence":9,"key_topics":["Adicet Bio Inc.","series B funding","gamma delta T cells","Non-Hodgkin’s Lymphoma","Marius Nacht"],"date_of_event":"2019-10-02","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$80 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"9iUrnYeDN8FYjAMDKX2jYSpVAFsJgKIQUHDMkeIduE20dXXoWot83t","news_summary":"Allogenic Immunotherapy Company Adicet Bio Raises $80 Million","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d4154237-43ce-45d8-8192-2836b85bede9","date":"Jan 27, 2016","link":"https://en.globes.co.il/en/article-adicet-buys-israeli-co-applied-immune-technologies-1001098743","source":"en.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"Applied Immune Technologies (AIT)","layoffs":null,"summary":"US biopharmaceutical company Adicet Bio, Inc. has acquired Israeli company Applied Immune Technologies, Ltd. (AIT), which develops immunotherapies. Adicet also announced the closure of a $51 million financing round led by OrbiMed Advisors LLC with the participation of Novartis Venture Fund and Pontifax. AIT will continue its operations in Israel as Adicets wholly-owned subsidiary.","partners":null,"customers":null,"investors":"OrbiMed Advisors LLC, Novartis Venture Fund, Pontifax","confidence":9,"key_topics":["Immunotherapy","Acquisition","Financing","Technology","Cancer"],"date_of_event":"January 27, 2016","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$51 million","structured_issues":["Acquisition","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7lvX3raxQ1SrqlHC8sZPubiEu8TrACxBl5V2oUcTebtESvOYDV9kdo","news_summary":"Adicet buys Applied Immune Technologies","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"extensions":null,"events":null,"hide_reasons":[{"id":"75T5aG1f0dpqYFonup40lXNjO046zUH82TaHW1TAiIMf9aYAsSOl0d","reason":"No relevant activity"},{"id":"7KVi9S7qqUtO0WCsFclwqBEZluejfNYqWC1Uhx0tPHtDxtvxPPaCPH","reason":"No longer active"},{"id":"hoyKAmu4YJEHmhtLwCdeFldSnDwaVbPXOnH0RA9hKHCzAcHO6OOrXd","reason":"Pending approval"},{"id":"TC54H7CXyKO8GmPECkbyKJf8n34r70JlfJTJHfo85exRpLaKI1Efs9","reason":"Pending approval - External entity"}],"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC75-_ICww","hub":null,"date":"2020-09-01","batch":"","token":"","amount":null,"hub_id":null,"source":"https://www.globenewswire.com/news-release/2020/09/15/2093777/0/en/Adicet-Announces-Completion-of-Merger-with-resTORbio.html","ticker":"ACET","enddate":"","mnatype":null,"eventtype":"POEvent","granttype":null,"valuation":null,"investment":[],"hub_logokey":null,"hub_urlname":null,"wasacquired":null,"delistreason":null,"capitalraised":null,"stockexchange":"NASDAQ","eventvisibility":"Public","amountvisibility":null,"duetoacquisition":null,"isextensionround":null,"token_visibility":"","fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCIutD_CQw","acquiredcompany_mna":null,"communitycompany_id":null,"isjointventuregrant":null,"acquiredcompany_spac":"Undisclosed","communitycompany_name":null,"communitycompany_type":null,"stockexchange_logokey":"$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","acquiredcompany_mna_id":null,"fundingtypefundingtype":null,"acquiredcompany_reverse":null,"acquiredcompany_spac_id":null,"communitycompany_hidden":null,"communitycompany_fullurl":null,"communitycompany_logokey":null,"communitycompany_urlname":null,"acquiredcompany_reverse_id":null,"acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":null,"acquiredcompany_mna_homepage":null,"acquiredcompany_spac_logokey":null,"acquiredcompany_spac_homepage":null,"acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":null,"acquiredcompany_reverse_homepage":null,"hub_logourl":"/assets/empty-state.svg","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$AU2PTNC6m8YQhSAZinm36kCeLZigl0lwDvuFvOK4ns8LMZtmlmhlUB","communitycompany_logourl":"/assets/empty-state.svg","acquiredcompany_mna_logourl":"/assets/empty-state.svg","acquiredcompany_spac_logourl":"/assets/empty-state.svg","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","style":"","hiddenCompanyTooltip":""}],"techcommunityinvolvement":null,"tags":["cell-therapy","pharmaceuticals","cancer","immunology"],"investments":[],"funds":[],"databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"1-500","fundingtype":"Multinational","parsedName":"Adicet Bio","logourl":"https://storage.googleapis.com/clean-finder-353810/$KQ6kToraT4NEfeKAnZ6Yp1ascOVlqB9MKFAM8alQARaOWykOaWHU6I","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$KQ6kToraT4NEfeKAnZ6Yp1ascOVlqB9MKFAM8alQARaOWykOaWHU6I","teamMembersNumber":2,"nationality":"Foreign","communityinvolvement":[],"popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none"},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}